There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heron Therapeutics (HRTX) and Apellis Pharmaceuticals (APLS) with bullish sentiments.
Heron Therapeutics (HRTX)
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Heron Therapeutics, with a price target of $35.00. The company’s shares closed last Wednesday at $18.40.
According to TipRanks.com, Byrnes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.7% and a 37.5% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Oncternal Therapeutics, Aridis Pharmaceuticals, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Heron Therapeutics is a Strong Buy with an average price target of $30.33.
See today’s analyst top recommended stocks >>
Apellis Pharmaceuticals (APLS)
Needham analyst Joseph Stringer assigned a Buy rating to Apellis Pharmaceuticals today and set a price target of $59.00. The company’s shares closed last Wednesday at $45.30.
According to TipRanks.com, Stringer has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.9% and a 38.1% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and Crispr Therapeutics AG.
Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $78.00, implying a 72.4% upside from current levels. In a report issued on April 16, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $130.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
